证券代码：603235 证券简称：天新药业 公告编号：2023-015 江西天新药业股份有限公司 关于参加江西辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，江西天新药业股份有限公司（以下简 称"公司"）将参加由江西证监局、江西省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年江西辖区上市公司投资者集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (https://rs.p5w.net)，或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 5 月 19 日（周五）14:30-17:00。届时公 司高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计 划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与。 特此公告。 江西天新药业股份有限公司 2023 年 5 ...

2023 年第一季度报告 证券代码：603235 证券简称：天新药业 2023 年第一季度报告 重要内容提示 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 □是 √否 (一)主要会计数据和财务指标 1 / 18 | --- | --- | --- | --- | |---------------------------------|------------------|------------------|---------------------------------------| | | | | | | 稀释每股收益（元/股） | | 0.25 | -44.44 | | 加权平均净资产收益率（%） | | 2.64 | 减少 6.27 个百分点 | | | 本报告期末 | 上年度末 | 本报告期末比上年度末 增减变动幅度 (%) | | | | | | | 总资产 | 4,740,703,136.99 | 4,679,962,858.74 | 1.30 | | 归属于上市公司股东的 所有者权益 | 4,169,064,254.29 | 4,0 ...

Financial Performance - Net profit attributable to parent company shareholders in 2022 was RMB 622,115,124.53[4] - Revenue for the period was 2.304 billion yuan, a decrease of 8.63% year-on-year[150] - Net profit attributable to shareholders of the listed company was 622.1151 million yuan, a decrease of 16.37% year-on-year[150] - Revenue for 2022 decreased by 8.63% to 2,304,791,038.35 RMB compared to 2,522,433,794.74 RMB in 2021[167] - Net profit attributable to shareholders decreased by 16.37% to 622,115,124.53 RMB in 2022 from 743,886,733.62 RMB in 2021[167] - Net cash flow from operating activities dropped by 25.90% to 606,613,170.14 RMB in 2022 from 818,631,084.40 RMB in 2021[167] - Total assets increased by 58.52% to 4,679,962,858.74 RMB at the end of 2022 compared to 2,952,268,631.24 RMB at the end of 2021[167] - Basic earnings per share decreased by 20.11% to 1.51 RMB in 2022 from 1.89 RMB in 2021[167] - Weighted average return on equity (ROE) decreased by 26.78 percentage points to 21.78% in 2022 from 48.56% in 2021[167] - Revenue for 2022 was RMB 23,047.91 million, a decrease of 8.63% year-over-year[189] - Net profit attributable to shareholders was RMB 6,221.15 million, down 16.37% year-over-year[189] - Total assets at the end of 2022 were RMB 4,679.96 million, an increase of 58.52% year-over-year[189] - Shareholders' equity was RMB 4,057.98 million, up 112.60% year-over-year[189] - Basic earnings per share were RMB 1.51, a decrease of 20.11% year-over-year[189] - Main business revenue was RMB 22,530.80 million, down 8.65% year-over-year, mainly due to decreased sales volume and prices of vitamin products[191] - Main business costs were RMB 14,014.35 million, up 1.45% year-over-year, primarily due to rising raw material prices and manufacturing expenses[191] Dividend Distribution - The company plans to distribute a cash dividend of RMB 7.10 per 10 shares, totaling RMB 310,823,800.00, representing 49.96% of the net profit attributable to shareholders[4] - The company's cash dividend ratio meets the requirements of the "Post-Listing Shareholder Dividend Return Plan for the First Three Years"[4] Share Capital and Reserves - The company's total share capital as of December 31, 2022, was 437,780,000 shares[4] - The company's accumulated undistributed profit of the parent company was RMB 1,394,464,073.49[4] - The capital reserve balance of the parent company was RMB 2,011,888,673.74[4] Accounting Policies - The company's internal R&D expenditure accounting policy is applicable[11] - The company's long-term assets are subject to impairment testing if there are signs of potential impairment[12] - The company's income recognition and measurement accounting policy is applicable[22] - Deferred tax assets and liabilities are recognized based on temporary differences between book and tax values[26] - Deferred tax assets are recognized only if future taxable income is likely to be available to utilize the deductions[26] - Deferred tax liabilities are recognized for all taxable temporary differences except in specific cases[26] - Net settlement of current tax assets and liabilities is allowed under certain conditions[26] Government Subsidies and Tax Benefits - Government subsidies are classified into asset-related and income-related subsidies, with specific criteria for classification[25] - Asset-related subsidies are deferred and recognized as income over the useful life of the asset[25] - Income-related subsidies are either deferred or directly recognized in the current period depending on their purpose[25] - The company passed the high-tech re-certification in 2022 and obtained the high-tech enterprise certificate (certificate number: GR202236000707) from the Jiangxi Provincial Department of Science and Technology, Jiangxi Provincial Department of Finance, and Jiangxi Provincial Taxation Bureau of the State Taxation Administration, allowing it to enjoy a preferential corporate income tax rate of 15% from 2022 to 2024[34] - Government subsidies received in 2021 amounted to 54,253,538.72 RMB[171] Environmental and Social Responsibility - The company strictly complies with national and local environmental protection laws and regulations, ensuring that its production and operations meet environmental requirements[37] - The company donated funds benefiting 100 people at the Le Ping Secondary Vocational School, while the number of beneficiaries from donations to the Le Ping Red Cross could not be counted[39] - The company's environmental protection investment in 2022 was 139.29 million yuan[65] - The company was awarded the 2022 National Green Factory title[150] Inventory and Receivables - The company's inventory of goods increased by 1,674,960.20 yuan during the period[84] - The company's turnover materials increased by 995,783.25 yuan during the period, reaching 2,255,545.81 yuan at the end of the period[84] - The company's issued goods increased by 625,732.57 yuan during the period[84] - Inventory includes raw materials valued at RMB 83,181,066.22, work in progress at RMB 104,241,924.69, and finished goods at RMB 198,481,876.92, with a provision for inventory impairment of RMB 1,674,960.20[99] - Accounts receivable within one year amount to RMB 273,050,431.31, representing the majority of the total accounts receivable[108] - Accounts receivable with a provision for bad debts of 13,652,521.57 yuan, accounting for 5.00% of the total receivables[114] - Total accounts receivable at the end of the period amounted to 273,050,431.31 yuan[114] - The top five other receivables account for 94.93% of the total other receivables, with a total balance of RMB 4,050,939.63[98] - The company's other receivables totaled 4,267,191.08 yuan at the end of the period, with deposits and guarantees accounting for 2,952,497.50 yuan[51] - The company's prepayments for the year-end amounted to 11,968,569.83 yuan, with 99.73% being within 1 year[76] - The company's prepayments for the top five prepayment objects at the end of the period are not disclosed[77] - The company's bad debt provision for other receivables is not applicable[81] - Bad debt provision for the portfolio is RMB 17,500,552.51, with a decrease of RMB 3,848,030.94, resulting in a net provision of RMB 13,652,521.57[90] - The balance of bad debt provision as of December 31, 2022, is RMB 2,233,308.13, with a provision of RMB 614,091.07 during the period[95] - The balance of bank acceptance bills under the portfolio provision is RMB 80,828,011.60, accounting for 100% of the total[107] - Bank acceptance bills increased from RMB 7,091,074.35 to RMB 17,085,204.24, showing significant growth[91] - Bank acceptance bills at the end of the period totaled 80,828,011.60 yuan, with 60,012,793.35 yuan not yet confirmed for termination[128][129] - The company has no actual write-offs of receivables financing during the period[124] - No pledged receivables financing at the end of the period[124] - No receivables financing transferred to accounts receivable due to non-performance by the issuer at the end of the period[130] Cash Flow and Financial Assets - The company's operating cash flow was 131.2937 million yuan[143] - The company's trading financial assets increased by 230 million yuan due to short-term bank wealth management products[147] - Monetary funds at the end of the period totaled 2,069,864,246.58 yuan, with bank deposits accounting for 2,069,269,364.63 yuan[125] - Trading financial assets at the end of the period amounted to 230,000,000.00 yuan, primarily consisting of short-term bank wealth management products[126] Product and Market Performance - Vitamin business accounted for 97.87% of the company's main business revenue[157] - The company achieved self-production of the key intermediate ABL for Vitamin B1 in 2021 and began external sales in 2022[150] - The company's product prices remained at historically low levels, contributing to the 2022 performance decline[157] - China's vitamin production in 2022 was 408,000 tons, a decrease of 2.1% year-over-year, accounting for 83.4% of global production[179] - China's vitamin market value in 2022 was USD 4.09 billion, a decrease of 11.7% year-over-year[179] - The company holds a leading global market share in Vitamin B6 and Vitamin B1, and is in the top tier for biotin and folic acid products[179] - B-vitamin and other vitamin product revenues decreased due to lower sales volume and prices amid industry supply-demand pressures[194] - Fine chemical product revenues increased significantly due to the sale of ABL products during the reporting period[194] - ABL product achieved external sales during the reporting period[199] Costs and Expenses - Raw material costs for nutritional products decreased by 5.70% compared to the same period last year[196] - Manufacturing costs for nutritional products increased by 5.18% compared to the same period last year[196] - Total costs for nutritional products decreased by 1.41% compared to the same period last year[196] - Raw material costs for other products increased by 6,560.31% compared to the same period last year[196] - Manufacturing costs for other products increased by 10,610.92% compared to the same period last year[196] - Total costs for other products increased by 3,382.33% compared to the same period last year[196] Non-Recurring Items - Non-recurring gains and losses amounted to 54.3241 million yuan[146] Company Information - The company's registered address is in the Leanjiang Industrial Park, Leping City, Jiangxi Province[163] - The company's website is http://www.txpharm.com/[163] - The company's legal representative is Xu Jiangnan[163] Risk Management - The company has no significant risk exposure as detailed in the management discussion and analysis section[117] Customer Concentration - Top 5 customers accounted for 18.90% of total accounts receivable[198] Research and Development - The company's R&D expenses grew rapidly, laying the foundation for sustainable development[157] - The company's contract performance cost for the period was 707,863.88 yuan[84]

2022 年第三季度报告 单位：元 币种：人民币 证券代码：603235 证券简称：天新药业 江西天新药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 项目 本报告 期 上年同期 本报告 期比上 年同期 增减变 动幅度 (%) 年初至 报告期 末 上年同期 年初至 报告期 末比上 年同期 增减变 动幅度 (%) 调整前 调整后 调整后 调整前 调整后 调整后 1 / 19 2022 年第三季度报告 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------- ...

2022 年半年度报告 公司代码：603235 公司简称：天新药业 江西天新药业股份有限公司 2022 年半年度报告 1 / 137 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人许江南、主管会计工作负责人罗雪林及会计机构负责人（会计主管人员）梁亮声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 本公司面临的重大风险主要包括产品价格波动风险 ...